DNA去甲基化剂联合全反式维甲酸治疗IDH1突变胶质瘤的评估
本文为临床前研究,评估5-阿扎胞苷(5-Aza)联合全反式维甲酸(atRA)对IDH1突变胶质瘤细胞增殖、凋亡和基因表达的影响,并在携带IDH1R132H突变的患者来源异种移植(PDX)皮下和原位模型中测试疗效。结果显示联合用药在体外降低细胞生长、增加分化标志物表达和凋亡,并显著降低皮下肿瘤生长速率,但在原位小鼠模型中联合用药未改善生存,5-Aza单药提供最佳生存获益。
要点
- 5-Aza降低DNA甲基化并上调维甲酸相关基因表达。
- 5-Aza联合atRA在IDH1R132H胶质瘤细胞中减少生长、增加分化标志和凋亡。
- 联合用药显著降低皮下肿瘤生长速率,但原位模型未改善生存,5-Aza单药生存获益最佳。
核心结论
- DNA去甲基化剂联合维甲酸类药物显示出应用前景,但用于治疗颅内IDH突变胶质瘤仍需进一步优化和临床前研究。
研究设计与样本
- 临床前研究,评估5-Aza和atRA联合对人胶质瘤细胞增殖、凋亡和基因表达的影响。
- 在携带IDH1R132H突变的患者来源异种移植(PDX)皮下和原位模型中测试联合用药疗效。
主要发现
- 5-Aza降低DNA甲基化谱并增加维甲酸相关基因表达。
- 5-Aza联合atRA减少IDH1R132H胶质瘤细胞生长、增加分化标志物表达和凋亡。
- 5-Aza通过上调维甲酸通路使IDH1R132H胶质瘤细胞对atRA敏感。
- 联合用药显著降低皮下肿瘤生长速率,但在原位小鼠模型中联合用药未改善生存,5-Aza单药提供最佳生存获益。
局限性
- 原文结论指出用于治疗颅内IDH突变胶质瘤仍需进一步优化和临床前研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Isocitrate Dehydrogenase 1/2 (IDH1/2) mutations are diagnostic for Astrocytoma or Oligodendroglioma, IDH-mutant. In these IDH-mutant gliomas, retinoic acid-related gene expression is commonly silenced by DNA hypermethylation. DNA demethylating agents can epigenetically reprogram IDH-mutant cells and reduce proliferation, likely by re-expression of silenced tumor suppressor pathways. We hypothesized that DNA demethylation might restore the retinoic acid pathway and slow tumor growth. This was the rationale for a preclinical evaluation combining the DNA demethylating agent, 5-Azacytidine (5-Aza), and retinoic acid pathway activation with all-trans retinoic acid (atRA) in IDH-mutant glioma. METHODS: In this study, we evaluated the effect of 5-Aza and atRA combination on cell proliferation, apoptosis, and gene expression in human glioma cells. In addition, the efficacy of this combination was tested in patient-derived xenograft (PDX) bearing the IDH1R132H mutation, utilizing subcutaneous and orthotopic models. RESULTS: 5-Aza reduced the DNA methylation profile and increased the gene expression of retinoic acid-related genes. Combination of 5-Aza and atRA reduced cell growth, increased differentiation marker expression, and apoptosis in IDH1R132H glioma cells. Mechanistically, 5-Aza sensitized IDHIR132H glioma cells to atRA via upregulation of the retinoic acid pathway. Importantly, the drug combination reduced significantly the growth rate of subcutaneous tumors, but in an orthotopic mouse model, the combination did not improve survival and 5-Aza alone provided the best survival benefit. CONCLUSION: Use of DNA demethylating agent in combination with retinoids shows promise, but further optimization and preclinical studies are required for treatment of intracranial IDH-mutant gliomas.
引用
- da Costa Rosa M, Yamashita AS, Riggins GJ, et al. Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas. Neuro Oncol. 2022. PMID: 34850159. doi:10.1093/neuonc/noab263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。